logo
Opera files complaint against Microsoft's tricks to make you use Edge

Opera files complaint against Microsoft's tricks to make you use Edge

The Verge7 days ago
Microsoft has used a variety of tricks to convince people to keep using the defaults of Bing and Microsoft Edge in Windows over the years, including modifying Chrome download sites and using malware-like popups. Now, Opera is fed up of what it calls Microsoft's 'manipulative design tactics' and is filing a competition complaint in Brazil today, alleging that Microsoft is using anti-competitive practices to steer people toward using Edge.
'Microsoft thwarts browser competition on Windows at every turn,' says Aaron McParlan, general counsel at Opera. 'First, browsers like Opera are locked out of important preinstallation opportunities. And then Microsoft frustrates users' ability to download and use alternative browsers.'
Opera's complaint alleges that Microsoft ignores a users' default browser choice in a variety of ways, from opening PDF files or links in Outlook and Teams, to opening links through Windows features like Search or Widgets. Opera also notes that Microsoft uses 'obtrusive banners and messages discouraging users fromdownloading alternative browsers at the very moment they are searching for those browsers on Edge.'
Opera has filed its complaint in Brazil because it's one of the company's main markets. 'Opera is already a major success in Brazil: it is the third most popular browser in Brazil and has millions of loyal users in Brazil who actively choose it, despite Microsoft's tactics,' says McParlan, in a statement to The Verge. 'The complaint, which concerns practices implemented globally by Microsoft, presents an opportunity for Brazil to be a leader on this international issue'
If Opera is successful with its complaint, it wants remedies from Microsoft like allowing PC manufacturers to preload alternative default browsers, a halt to blocking consumers from downloading other browsers, and an end to 'dark patterns that push users towards Edge.' Opera also reveals that Microsoft requires OEMs to 'deliver S mode devices as a condition for rebates on a Windows OS license,' which is another practice it wants to see outlawed.
While the complaint will be handled by Brazil's competition authority, it's part of a broader effort from Opera to challenge Microsoft's Edge practices around the world. Opera unsuccessfully challenged the EU's decision not to designate Microsoft Edge as a gatekeeper under its Digital Markets Act (DMA) rules last year. Microsoft escaped this designation, but it has still had to make changes to Windows in EU markets in response to the DMA. These changes have led to it stop bugging Windows users about Edge.
'We believe that Microsoft's conduct, including the changes that it has announced in Europe, are insufficient to attain effective compliance with the DMA,' says McParlan. 'In this context, and as part of its global efforts to ensure free and effective consumer choice, Opera has appealed before the EU Courts the European Commission's decision not to designate Edge as a 'gatekeeper' service under the DMA.'
Not only has Microsoft used Windows to urge people into switching to Edge in the past, the company also created a spoofed Google UI to try and convince Bing users they were using Google earlier this year. The search results looked a lot like Google, complete with a custom search bar, Google Doodle-like image, and some small text under the search bar just like Google search. Microsoft quickly killed the plug on its spoofed Google UI once people started noticing it.
Opera also has a history of complaints against Microsoft's browser behavior in Windows. It originally filed an antitrust complaint with the EU in 2007, which eventually led to the browser ballot screen being created — allowing Windows users to pick one of the 12 most popular browsers rather than defaulting to Internet Explorer. Microsoft had to keep the browser choice screen in Windows for five years, but was fined $730 million in 2013 for failing to include the ballot in Windows 7 Service Pack 1.
Posts from this author will be added to your daily email digest and your homepage feed.
See All by Tom Warren
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Microsoft
Posts from this topic will be added to your daily email digest and your homepage feed.
See All News
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Policy
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Tech
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Web
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Windows
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New US-EU trade deal on tariffs ends pharma's geopolitical immunity
New US-EU trade deal on tariffs ends pharma's geopolitical immunity

Yahoo

time25 minutes ago

  • Yahoo

New US-EU trade deal on tariffs ends pharma's geopolitical immunity

For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU. On 27 July, the US government announced a 15% tariff on branded pharmaceutical products imported from the EU. Despite the decrease from the original 30% tariff on pharmaceuticals earlier in the year, this disrupts a long-established practice of the exemption of medicines from tariffs due to their importance in public health. The 15% tariff is not expected to happen immediately as implementation will be dependent on a National Security investigation regarding pharmaceutical imports. This trade deal puts the pharmaceutical industry at risk of losing between $13bn and $19bn, with consequences that extend beyond short-term financials. It will force pharmaceutical companies to make a tradeoff between tightening their profit margins and increasing drug prices, with both paths posing a risk to patient access and payer relations. The imposition of tariffs threatens to elevate costs across the pharmaceutical value chain, and could lead to a substantial increase in drug development costs, manufacturing, and distribution, with global supply chains for active pharmaceutical ingredients (APIs), raw materials, and equipment directly exposed. This disruption could create uncertainty in launch planning, particularly for late-stage assets with EU-based manufacturing and production planned for US entry. Companies manufacturing pharmaceutical products in Europe will need to anticipate financial exposure when planning launches in the US due to the unfavourable gross-to-net dynamics, weakened pricing leverage with US payers, and slower commercial uptake as insurers reassess cost-effectiveness due to the tariffs. Research and development budgets are already under pressure, and may be further strained as pharmaceutical companies may have to divert budget to firefight the impact of the tariffs. This could hinder innovation and pipeline investment, reducing the much-needed pace of therapeutic innovation across the industry. Earlier in the year, the US administration did signal tariffs for pharmaceutical imports could become a real possibility; this was met with proactive US investment from leading pharmaceutical companies to onshore manufacturing in the US to reduce exposure. Most recently, in July 2025, Biogen announced a $2bn investment into North Carolina, strengthening its US manufacturing position. Other pharmaceutical companies such as Johnson & Johnson, AstraZeneca, and Eli Lilly have also increased their investment in US manufacturing, with investments of $55bn, $50bn, and $27bn, respectively. Ultimately, the recent US-EU trade deal has increased the level of uncertainty within the pharmaceutical industry, raising concerns about the potential of tariffs increasing past 15% in the future. A once-shielded sector is facing a geopolitical shift, leaving the pharmaceutical industry vulnerable to global volatility. "New US-EU trade deal on tariffs ends pharma's geopolitical immunity" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Increased Investor Confidence and Better Than Expected Results Boosted Microsoft (MSFT) in Q2
Increased Investor Confidence and Better Than Expected Results Boosted Microsoft (MSFT) in Q2

Yahoo

time25 minutes ago

  • Yahoo

Increased Investor Confidence and Better Than Expected Results Boosted Microsoft (MSFT) in Q2

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its 'RiverPark Large Growth Fund' Q2 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets surged in the second quarter, with the S&P 500 Total Return Index rising 10.94% and the Russell 1000 Growth Index returning 17.84%. The fund also surged in the quarter and returned 15.01%. Continued enthusiasm for artificial intelligence, better-than-expected earnings in several large-cap growth sectors, and improving macroeconomic conditions lifted the markets in the quarter. Growth-focused stocks took the lead once more, with the strongest performance coming from sectors like technology, communication services, and certain areas of consumer discretionary. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, RiverPark Large Growth Fund highlighted stocks such as Microsoft Corporation (NASDAQ:MSFT). Microsoft Corporation (NASDAQ:MSFT) is a multinational software company that develops and supports software, services, devices, and solutions. The one-month return of Microsoft Corporation (NASDAQ:MSFT) was 7.86%, and its shares gained 34.04% of their value over the last 52 weeks. On August 4, 2025, Microsoft Corporation (NASDAQ:MSFT) stock closed at $535.64 per share, with a market capitalization of $3.982 trillion. RiverPark Large Growth Fund stated the following regarding Microsoft Corporation (NASDAQ:MSFT) in its second quarter 2025 investor letter: "Microsoft Corporation (NASDAQ:MSFT): MSFT delivered strong second-quarter performance, aided by better-than-expected results and growing investor confidence in its enterprise AI strategy. In its April earnings release, Microsoft reported Azure growth of 31% year-over-year, its highest rate in over 18 months. The Productivity and Business Processes segment also performed well, supported by Microsoft 365, Teams, and Dynamics. Microsoft's Build 2025 conference in May featured Copilot Studio updates and expanded integration of generative AI into its platform offerings. A development team working together to create the next version of Windows. Microsoft Corporation (NASDAQ:MSFT) is in second position our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 284 hedge fund portfolios held Microsoft Corporation (NASDAQ:MSFT) at the end of the first quarter compared to 317 in the previous quarter. In the fourth quarter of fiscal year 2025, Microsoft Corporation (NASDAQ: MSFT) reported revenue of $76.4 billion, representing an 18% increase, or 17% when adjusted for constant currency. While we acknowledge the potential of Microsoft Corporation (NASDAQ:MSFT) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Microsoft Corporation (NASDAQ:MSFT) and shared the list of AI stocks analysts are watching closely. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Broadcom Supercharges AI Infrastructure With Next-Gen Chip
Broadcom Supercharges AI Infrastructure With Next-Gen Chip

Yahoo

time25 minutes ago

  • Yahoo

Broadcom Supercharges AI Infrastructure With Next-Gen Chip

Broadcom (NASDAQ:AVGO) announced on Monday that it has begun shipping the Jericho4 ethernet fabric router, a purpose-built platform designed for the next generation of distributed AI infrastructure. Broadcom built the Jericho4 networking chip to meet the growing demands of hyperscalers like Microsoft (NASDAQ:MSFT) and (NASDAQ:AMZN) as they scale AI infrastructure. Engineered to connect data centers up to 60 miles apart, Jericho4 accelerates AI workloads by managing massive volumes of network traffic with high-bandwidth memory typically used in GPUs from Nvidia (NASDAQ:NVDA) and Advanced Micro Devices (NASDAQ:AMD).Broadcom designed Jericho4 to interconnect over one million XPUs across multiple data centers, breaking traditional scaling limits with unmatched bandwidth, security, and lossless performance. Together with the Tomahawk 6 and Tomahawk Ultra, Jericho4 completes Broadcom's comprehensive networking portfolio for HPC and AI. As AI models grow in size and complexity, infrastructure demands now exceed single data centers' power and physical limits. To meet these demands, engineers must distribute XPUs across multiple facilities, each equipped with tens to hundreds of megawatts of power. This shift requires a new class of router optimized for secure, lossless, high-bandwidth transport across regional distances. By leveraging deep buffering and intelligent congestion control, Jericho4 ensures lossless RoCE across 100km+ distances, enabling a truly distributed AI infrastructure that is not limited by power or space at any single site. Built on a 3nm process, Jericho4 integrates Broadcom's advanced 200G PAM4 SerDes, offering industry-leading reach. This design eliminates the need for retimers and other additional components, lowering power consumption, reducing costs, and improving system reliability. Broadcom stock gained close to 29% year-to-date, topping the NASDAQ 100 Index by over 10%, backed by the AI frenzy. Broadcom leads the Application-Specific Integrated Circuit (ASIC) market by designing and manufacturing custom silicon chips tailored for high-performance computing, networking, and storage. The company prioritizes speed and efficiency, delivering advanced solutions that power data centers and specialized computing infrastructure. Meta Platforms (NASDAQ:META), Microsoft, and Alphabet (NASDAQ:GOOGL) are driving a $250 billion surge in AI infrastructure through 2025–26, demonstrating their commitment to powering the next industrial revolution. These tech giants are rapidly increasing capital expenditures on data centers, servers, and networking to scale AI development, turning bold ambitions into concrete infrastructure. Price Action: AVGO stock is trading higher by 0.38% to $298.86 premarket at last check Tuesday. Photo by Tada Images via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? BROADCOM (AVGO): Free Stock Analysis Report This article Broadcom Supercharges AI Infrastructure With Next-Gen Chip originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store